Status: Planned
First registered on:
13/11/2019
Last updated on:
18/11/2019
1. Study identification
EU PAS Register NumberEUPAS32302
Official titleEvaluation of the effectiveness of pregnancy prevention programme (PPP) for oral retinoids (acitretin, alitretinoin, and isotretinoin): a European before-after drug utilization study (DUS) using secondary data
Study title acronym
Study typeOther: Drug Utilization Study
Brief description of the study
Was this study requested by a regulator?Yes: EMA
Is the study required by a Risk Management Plan (RMP)?
EU RMP category 1 (imposed as condition of marketing authorisation)
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsIQVIA
Department/Research groupReal World Solutions
Organisation/affiliationIQVIA
Details of (Primary) lead investigator
Title Dr
Last name Toussi
First name Massoud
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
International study
France
Germany
Spain
Sweden
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed30/06/2018
Start date of data collection01/07/2021
Start date of data analysis
Date of interim report, if expected
Date of final study report31/12/2022
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesOral Retinoids Consortium consisting of 31 Marketing Authorisation Holders100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Toussi
First name Massoud
Address line 1Tour D2
Address line 217 bis Place des Reflets
Address line 3
CityCourbevoie
Postcode92090
CountryFrance
Phone number (incl. country code)0033607966650
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Ms
Last name Dwan
First name Bernadette
Address line 1Theaterstrasse 4
Address line 2
Address line 3
CityBasel
Postcode
CountrySwitzerland
Phone number (incl. country code)0041754335843
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Substance class (ATC Code)D05BB02 (acitretin)
Substance class (ATC Code)D11AH04 (alitretinoin)
Substance class (ATC Code)D10BA01 (isotretinoin)
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Sex
Female
9. Number of subjects
Estimated total number of subjects150000
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Data sources not registered with ENCePP
Système National d'Information Inter-Régimes de l'Assurance Maladie (SNIIRAM), France
Company Health Insurance funds, Germany
Swedish national patient register, Sweden
Swedish national birth register, Sweden
Sources of data
Administrative database, e.g. claims database
Routine primary care electronic patient registry
11. Scope of the study
What is the scope of the study?
Drug utilisation study
Effectiveness evaluation
Primary scope : Drug utilisation study
12. Main objective(s)
What is the main objective of the study?
The main objective of the study is to assess if there is a difference in physicians' prescribing and monitoring practice in the periods before and after the update of the pregnancy prevention programme (PPP) for the oral retinoids acitretin, alitretinoin, and isotretinoin when treating women of childbearing potential?
Are there primary outcomes?Yes
To evaluate the changes in the prescribing and monitoring practices following the update of the PPP in females of childbearing potential receiving prescriptions of the oral retinoids acitretin, alitretinoin, or isotretinoin by comparing contraceptive use, prescription interval, and laboratory preganancy tests in the period before and after the implementation of the updated PPP
Are there secondary outcomes?Yes
The secondary outcome of the study is to described the patient profile, the prescriber profile, the exposure characteristics, incidence of pregnancies during oral retinoid exposure, trends in the physician's prescribing and monitoring practice, and assess the elements of the primary outcomes by active substance.
13. Study design
What is the design of the study?
Drug utilisation study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
The data extracted from the data sources will be analysed by country and by active substance for the elements of the primary outcomes. The analysis will descriptively analyse the prescribing and monitoring patterns in females of childbearing potential treated with oral retinoids before and after the implementation of the updated pregnancy prevention programme. The secondary outcomes will be analysed descriptively as well. To assess the trends in the prescribing and monitoring practice of oral treatment, an interrupted time series analysis will be performed.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Not submitted
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
